Original Source(s)
Related Content
FDA approves first at-home therapy for thyroid eye disease
The first at-home subcutaneous treatment for thyroid eye disease met its primary end point in 1 of 2 phase 3 trials.
by Mouj Hijazi
October 16, 2026
-
2 min
4 societies redefine women's heart care
New multisociety guidance identifies menstrual irregularities as potential early markers of cardiovascular risk, extending prevention efforts into adolescence.
by Teraya Smith
October 27, 2026
-
3 min
Digoxin misses heart failure endpoint
Researchers observed fewer worsening heart failure events, but the trial did not establish a statistically significant benefit.
by Kerri Miller
October 29, 2026
-
5 min
